within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BN02_Covid19ViralVectorNonReplicating;
model Covid19ViralVectorNonReplicating 
   extends Pharmacolibrary.Drugs.ATC.J.J07BN02;

  annotation(Documentation(
    info ="<html><body><p>COVID-19 vaccines of the viral vector, non-replicating type (e.g., ChAdOx1 nCoV-19/AstraZeneca and Ad26.COV2.S/Johnson & Johnson) use non-replicating adenovirus vectors to deliver genetic material encoding SARS-CoV-2 spike protein. These vaccines are used for prevention of COVID-19 and are authorized for emergency or standard use in many countries worldwide.</p><h4>Pharmacokinetics</h4><p>No formal pharmacokinetic (PK) studies are conducted for non-replicating viral vector COVID-19 vaccines in humans, as traditional PK parameters do not apply to vaccines. Estimated values based on typical administration to healthy adults.</p><h4>References</h4><ol><li><p>Marquez-Martinez, S, et al., &amp; Khan, S (2024). Peak transgene expression after intramuscular immunization of mice with adenovirus 26-based vector vaccines correlates with transgene-specific adaptive immune responses. <i>PloS one</i> 19(4) e0299215â€“None. DOI:<a href=&quot;https://doi.org/10.1371/journal.pone.0299215&quot;>10.1371/journal.pone.0299215</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38626093/&quot;>https://pubmed.ncbi.nlm.nih.gov/38626093</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Covid19ViralVectorNonReplicating;
